The public health control of scabies: priorities for research and action. by Engelman, Daniel et al.
LSHTM Research Online
Engelman, Daniel; Cantey, Paul T; Marks, Michael; Solomon, Anthony W; Chang, Aileen Y; Chosi-
dow, Olivier; Enbiale, Wendemagegn; Engels, Dirk; Hay, Roderick J; Hendrickx, David; +14 more...
Hotez, Peter J; Kaldor, John M; Kama, Mike; Mackenzie, Charles D; McCarthy, James S; Mar-
tin, Diana L; Mengistu, Birhan; Maurer, Toby; Negussu, Nebiyu; Romani, Lucia; Sokana, Oliver;
Whitfeld, Margot J; Fuller, L Claire; Steer, Andrew C; (2019) The public health control of sca-
bies: priorities for research and action. LANCET, 394 (10192). pp. 81-92. ISSN 0140-6736 DOI:
https://doi.org/10.1016/S0140-6736(19)31136-5
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4653773/
DOI: https://doi.org/10.1016/S0140-6736(19)31136-5
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
1 
Title: The public health control of scabies: priorities for research and action 
Short title: Research priorities for scabies control 
 1 
Authors: 
Daniel Engelman, PhD 
a. Tropical Diseases, Murdoch Children’s Research Institute, Melbourne, Victoria, 
Australia 
b. Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia 
c. General Medicine, Royal Children’s Hospital, Melbourne, Victoria, Australia 
 
Paul T Cantey, MD 
Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, 
Switzerland 
 
Michael Marks, PhD 
Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School 
of Hygiene & Tropical Medicine, London, UK 
 
Anthony W Solomon, PhD 
Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, 
Switzerland 
 
Aileen Y Chang, MD 
Department of Dermatology, University of California San Francisco, San Francisco, 
California, USA  
 
Prof Olivier Chosidow, PhD 
a. Department of Dermatology, Hôpital Henri-Mondor, AP–HP, Créteil, France;  
b. Université Paris-Est Créteil Val-de-Marne, Créteil, France. 
 
Wendemagegn Enbiale, MD 
Department of Dermatovenerology, College of Medicine and Health Sciences, Bahir Dar 
University, Bahir Dar, Ethiopia 
 
Dirk Engels, MD 
United to Combat Neglected Tropical Diseases, Switzerland 
 
Prof Roderick J Hay, DM 
Department of Dermatology, King’s College, London, United Kingdom 
 
David Hendrickx, PhD 
Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia 
 
 
 
2 
Prof Peter J Hotez, PhD 
Departments of Pediatrics and Molecular Virology and Microbiology, National School of 
Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA  
 
Prof John M Kaldor, PhD 
The Kirby Institute, University of New South Wales, Sydney, Australia 
 
Mike Kama, MBBS 
Ministry of Health and Medical Services, Suva, Fiji 
 
Prof Charles D Mackenzie, PhD 
The Taskforce for Global Health, Decatur, Georgia, USA 
 
Prof James S McCarthy, PhD 
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia 
 
Diana L Martin, PhD 
Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, 
Atlanta, Georgia, USA 
 
Birhan Mengitsu, MPH 
Federal Ministry of Health, Addis Ababa, Ethiopia 
 
Prof Toby Maurer, MD.  
Department of Dermatology, University of California, San Francisco. San Francisco, 
California, USA 
 
Nebiyu Negussu, MPH 
Federal Ministry of Health, Addis Ababa, Ethiopia 
 
Lucia Romani, PhD 
The Kirby Institute, University of New South Wales, Sydney, Australia 
 
Oliver Sokana, MPH 
Ministry of Health and Medical Services, Honiara, Solomon Islands 
 
Margot J Whitfeld, FACD 
Department of Dermatology, St Vincent’s Hospital, University of New South Wales, Sydney, 
Australia 
 
L Claire Fuller, FRCP 
a. Chelsea and Westminster Healthcare NHS Foundation Trust, London, UK  
b. International Foundation for Dermatology, London, UK 
 
Prof Andrew C Steer, PhD 
a. Tropical Diseases, Murdoch Children’s Research Institute, Melbourne, Victoria, 
Australia 
b. Paediatrics, University of Melbourne, Melbourne, Victoria, Australia 
c. General Medicine, Royal Children’s Hospital, Melbourne, Victoria, Australia 
 
3 
 
Corresponding Author: 
Daniel Engelman 
Murdoch Children’s Research Institute 
50 Flemington Road, Parkville, Victoria, 3052, Australia 
Phone: + 61 3 9345 5522  
Fax: + 61 3 9345 6667 
Email: Daniel.Engelman@rch.org.au 
  
4 
Summary 2 
Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged 3 
populations. Scabies causes considerable morbidity and leads to severe bacterial infection and 4 
immune-mediated disease. Recent scientific advances suggest that scabies is amenable to 5 
population-level control, particularly through mass drug administration. In recognition of 6 
these issues, WHO added scabies to the list of neglected tropical diseases (NTDs) in 2017. In 7 
order to develop a global control program, key operational research questions must now be 8 
addressed. Standardised approaches to diagnosis and methods for mapping are required to 9 
further understand the burden of disease. The safety of treatments for young children, 10 
including with ivermectin and moxidectin, should be investigated. Studies are needed to 11 
inform optimum implementation of mass treatment, including the threshold for intervention, 12 
target, dosing, and frequency. Frameworks for surveillance, monitoring and evaluation of 13 
control strategies are also necessary. 14 
  15 
5 
Introduction 16 
In 2017, scabies was added to the World Health Organization (WHO) list of neglected 17 
tropical diseases (NTDs). Scabies was recommended to be included as a ‘category A’ NTD, 18 
defined as those conditions that fulfil all four specified criteria, and are recommended for 19 
large scale action in the portfolio of the NTD Department.1 In reaching this recommendation, 20 
the WHO NTD Strategic and Technical Advisory Group noted the need for further research 21 
to inform control strategy as well as key issues for programmatic implementation, including 22 
ensuring affordable access to oral medications and developing guidelines for their public 23 
health use.2 In March 2018, the WHO NTD Global Working Group on Monitoring and 24 
Evaluation discussed scabies for the first time. Key recommendations from that meeting 25 
included the need to better define the global burden; to integrate control efforts to capitalise 26 
on ivermectin-based programs for other NTDs; and to establish interim guidelines for public 27 
health interventions for scabies control.3 In this rapidly evolving context, we review major 28 
recent advances in the science of control of human scabies, and identify key operational 29 
research questions that need to be addressed to develop a global scabies control program. 30 
The burden of scabies 31 
Scabies is caused by infestation with the microscopic ectoparasite Sarcoptes scabiei var. 32 
hominis, and leads to severe itch, skin lesions and more serious complications due to bacterial 33 
superinfection (Figure 1). Transmission requires skin-to-skin contact, and there is no non-34 
human reservoir. Scabies occurs in all countries, but its distribution is not uniform. In high-35 
income settings, most cases are sporadic, and the predominant public health issue is the 36 
management of outbreaks in institutions such as hospitals and residential aged care facilities. 37 
A far greater burden of disease is found in low- and middle-income countries, where access 38 
to effective treatment is limited and population crowding increases the opportunities for 39 
transmission. Areas with hot, humid climates have the highest reported prevalence, most 40 
prominently island communities in the Pacific region and Central America, and Indigenous 41 
communities of northern Australia.4-6 In these settings, the community prevalence has been 42 
consistently estimated in the range of 20 – 30%, with a higher prevalence of up to 40 – 50% 43 
in children aged less than 18 years (Figure 2).7-9  44 
In other resource-limited settings where baseline prevalence is lower, change in 45 
environmental or socio-political conditions can be associated with epidemics,18 such as the 46 
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outbreak in the Amhara Region in Ethiopia that has been in progress since 2015 and has been 47 
estimated to affect more than one million people.19,20  Circumstances with substantial 48 
population crowding frequently lead to high levels of transmission, and outbreaks are 49 
common within schools, prisons and camps for refugees and internally displaced persons.21 50 
Scabies is one of the world’s most common illnesses. The Global Burden of Disease (GBD) 51 
Study 2016 estimated the global point prevalence of scabies to be around 147 million, with 52 
455 million annual incident cases.22 Further GBD analyses estimated that scabies caused 53 
approximately 3.8 million disability-adjusted life years (DALYs), ranking scabies as one of 54 
the most important NTDs.23 Scabies causes an age-adjusted morbidity burden similar to 55 
Haemophilus influenzae type B meningitis and acute lymphoid leukaemia.24 These GBD 56 
analyses are modelled on the small number of published reports on the prevalence of scabies. 57 
Of note, the disability weighting only considers the skin changes and itch directly caused by 58 
infestation.24 The estimated burden would be far greater if the morbidity and mortality caused 59 
by the complications of scabies were included (Figure 3). Scabies infestation causes a 60 
considerable proportion of bacterial skin infection (pyoderma) in many resource-limited 61 
settings, most commonly manifesting as infected sores (impetigo). 7,8,25,26 For example, 62 
Aboriginal children in Australia were 12 times more likely to develop impetigo when 63 
infected with the scabies mite,26 and studies from Pacific island nations have estimated the 64 
attributable risk of scabies as a cause of impetigo to be 41% – 93%.7,8,27 Scabetic lesions and 65 
traumatic scratching create breaches in the skin barrier that are a portal for bacterial entry. 66 
Scabies mite components such as serpins inhibit innate immune pathways including 67 
neutrophil function and directly promote the growth of Staphylococcus aureus and 68 
Streptococcus pyogenes.28-31  Skin infection due to these bacteria can lead to severe soft 69 
tissue infections and invasive disease. Infection with S. pyogenes can also lead to immune-70 
mediated complications including post-streptococcal glomerulonephritis and possibly acute 71 
rheumatic fever, which in turn contribute to chronic kidney disease and rheumatic heart 72 
disease (Figure 3).32,33 Quantification of the proportion of the burden of these serious health 73 
consequences attributable to scabies will give a more accurate estimate of the global burden 74 
of scabies and the potential benefit of scabies control. 75 
Diagnosis 76 
Both the mapping of scabies and population-level control are hampered by the lack of a 77 
reliable, reproducible and standardised approach to diagnosis. Two systematic reviews of 78 
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diagnostic methods found a lack of consistency in the approach to scabies diagnosis.34,35 79 
Microscopy of skin scrapings to visualise mites and eggs is highly specific but insensitive and 80 
operator dependent, and therefore generally not useful for field settings. In order to address 81 
this gap, an international panel of experts, convened by the International Alliance for the 82 
Control of Scabies (IACS) recently used a Delphi consensus method to develop the 2018 83 
IACS Criteria for Scabies Diagnosis in research and epidemiological settings.36 These criteria 84 
enable diagnosis and reporting in three bands of diagnostic certainty - confirmed, clinical and 85 
suspected scabies. A diagnosis of confirmed scabies requires identification of the mite on 86 
microscopy or non-invasive visualisation techniques such as videomicrosopy and 87 
dermoscopy.37 Clinical and suspected scabies categories rely on features of clinical history 88 
and examination. As such, the criteria can be adapted for use in a variety of settings, 89 
including field surveys, and may help to standardise reporting and the conduct of scabies 90 
research. Validation of these criteria in diverse environments is now required, followed by 91 
development of standardised training methods and materials.  92 
Although the current focus should be on development of diagnostics for mapping and 93 
surveillance, in future, objective diagnostic tests may be needed, particularly if areas of low-94 
endemicity transition to a target of disease elimination. A point-of care diagnostic test would 95 
be ideal for public health use. Direct skin-based testing for infestation using molecular 96 
techniques, including polymerase chain reaction38,39 and loop mediated isothermal 97 
amplification,40 have been proposed but none are currently ready for programmatic use. 98 
Development of ELISA-based tests to detect antibodies against scabies antigens41 has been 99 
hindered by cross-reactivity between antigens from scabies and house dust mites.42,43 If a 100 
specific antibody test for scabies was developed, in order for it to be diagnostic, further 101 
evaluation would need to ensure that measured antibody responses were directly associated 102 
with ongoing infestation and not a measure of previous exposure. 103 
In addition to molecular diagnostics, non-invasive mite visualisation methods should be 104 
further evaluated. These high-magnification methods allow direct, in vivo visualisation of the 105 
mite (and with some methods, determination of mite survival or demise after treatment) 106 
without extraction of the mite by skin-scraping.44,45 Although these devices are expensive and 107 
require specialised training, more simple and affordable videomicroscopes also permit 108 
accurate visualisation of the mite in vivo, and low cost dermatoscopes have been 109 
developed.46,47 Further investigation and standardisation of outcome measures using these 110 
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methods would assist in assessing the efficacy of new treatments, and possibly validation of 111 
mapping and confirmation of outbreaks.48 112 
Epidemiology and mapping 113 
Despite an expansion of research on scabies in the last decade, the development of a global 114 
strategy has been constrained by a lack of prevalence data from most countries, including 115 
those suspected to be at-risk based on routinely reported clinical data or geographic or 116 
socioeconomic characteristics. For example, a worldwide systematic review of published 117 
scabies prevalence estimates found 48 studies, of variable quality, with over-representation of 118 
countries in the Pacific region and large areas of the world having no published prevalence 119 
data.4 Experience from other NTDs suggests that the knowledge of disease burden gained 120 
through mapping is critical for stakeholder engagement, translational research and successful 121 
scale-up of control programs.49 122 
Given the logistic challenge and cost of detailed mapping for NTDs,50 a priority activity is the 123 
development of a simple, low-cost, rapid assessment tool to assist policy-makers in initially 124 
determining whether scabies is likely to be a public health problem in a given context. 125 
Standardised survey methods to map scabies prevalence would then be required for a more 126 
detailed estimate of disease burden and its variation within and between regions.  Survey 127 
methods could utilise the 2018 IACS Diagnostic criteria,36 if these criteria are found to be 128 
valid and reproducible. It may be possible to train non-expert examiners in a limited, brief 129 
skin examination, which could then be correlated with more detailed diagnostic methods.51 A 130 
similar approach has been used for trachoma, where a rapid assessment may be followed by a 131 
standardised mapping survey.52-55 Survey design will need to consider the most appropriate 132 
populations and settings in which to conduct mapping, including ease of access, spatial and 133 
age distributions of disease and community acceptability. For example, mapping of children 134 
attending school could be expected to provide a representation of the groups with the highest 135 
burden in a community. This may be efficient, practicable and amenable to integration with 136 
mapping for some other NTDs and other health and education programs.56,57 Formal 137 
comparison of school versus community based sampling would help determine how well 138 
school prevalence correlates with community prevalence.58,59 139 
Beyond national-level prevalence data, there is limited understanding of the epidemiology of 140 
specific high burden areas or populations within otherwise high-income or low-prevalence 141 
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settings. Recognized examples include disadvantaged Indigenous populations within 142 
Australia, New Zealand and Canada,26,60-62 imprisoned 63,64 and homeless populations,65 and 143 
among groups seeking asylum within Europe.66-68 Scabies is a disease of poverty and inequity 144 
and it is likely that sub-populations with higher burdens would be found in many otherwise 145 
high-income settings.69 146 
Institutional scabies outbreaks result in considerable morbidity, stigma and healthcare cost in 147 
high-income settings. These outbreaks are typically challenging to identify and manage, 148 
leading to lengthy delays in confirmation and control as well as substantial cost.70-73 Changes 149 
in social demography, particularly aging, mean that these outbreaks may become more 150 
common, and the development of appropriate public health strategies is therefore warranted. 151 
A deeper appreciation of the features of institutional outbreaks in high-income settings could 152 
be leveraged for control of scabies elsewhere.  153 
Transmission and complications 154 
Despite scabies being an ancient disease, our understanding of the drivers of transmission 155 
remains limited. Understanding transmission dynamics is important for investigating the 156 
comparative effects of different control strategies, including through mathematical 157 
modelling.74,75 The observed cycles of scabies prevalence in some temperate settings (leading 158 
to the misnomer “the seven-year itch”) previously raised the possibility of herd immunity. 159 
However, in many tropical settings, recurrent infestations are common and present with more 160 
rapid onset of symptoms than in the initial infection.43 Very high population prevalence is 161 
sustained in some of these settings, suggesting that variations across geographic regions and 162 
time are more likely explained by factors other than personal or herd immunity.76,77  163 
Of particular importance to transmission is the role of individuals with the rare clinical 164 
variant of crusted scabies (previously known as Norwegian scabies), usually in association 165 
with immunosuppression (disease or drug-related) or neurological illness. People with 166 
crusted scabies may carry thousands to millions of mites and are highly infectious, thereby 167 
acting as core transmitters within some communities.78 Failure to identify and manage these 168 
individuals may undermine the success of control programs.79 There is an incomplete 169 
understanding of why there are many individuals in northern Australia with crusted scabies in 170 
the absence of identifiable causes of immunosuppression, but relatively few such cases have 171 
been described in other high-prevalence settings.7,78,80,81 172 
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The pathogenic links between scabies, impetigo, the infectious complications of S. aureus 173 
and S. pyogenes and the immune-mediated complications of S. pyogenes need further 174 
investigation. If these high morbidity and mortality conditions can be more definitively 175 
linked with scabies, and can be shown to be effectively prevented through scabies control, the 176 
rationale to invest in scabies control will be more compelling for governments, potential 177 
donors and other stakeholders. The relevant associations have been considered most 178 
thoroughly in the Pacific region,61,82-84 where impetigo is very common, but the limited data 179 
from other regions suggest endemic scabies occurs in those environments with lower 180 
prevalence of impetigo.4 This pattern needs to be properly quantified and the reasons for any 181 
variation, if genuinely present, further explored. Impetigo caused by S. pyogenes is a major 182 
cause of acute glomerulonephritis,85 which in turn contributes to the high burden of chronic 183 
kidney disease in low-income settings.86 Scabies has been associated with chronic kidney 184 
disease in both epidemiological studies and case reports.87-89 Rheumatic heart disease is 185 
estimated to cause over 300,000 deaths per year, with a global distribution that overlaps with 186 
areas highly-endemic for scabies.90 A global resolution on rheumatic fever and rheumatic 187 
heart disease was adopted by the World Health Assembly in 2018.91 Primary prevention of 188 
streptococcal skin infection through scabies control could potentially be an important 189 
component of preventing these diseases.61 190 
Social and economic issues 191 
As a disease that affects the skin, scabies is a potent cause of stigma and reduced quality of 192 
life.11,92,93  Increasingly, the chronic disfigurement caused by scabies and other NTDs is 193 
understood to adversely affect mental health,56,94 although this aspect has not been factored 194 
into current GBD estimates of DALYs. Understanding the conception of scabies, itch and 195 
impetigo within various cultures will help define what ‘scabies as a public health problem’ 196 
means to the most affected communities. This research will also assist in building 197 
partnerships with communities to develop control intervention, and to maximise participation 198 
in them. Scabies is often incorrectly attributed to ‘poor hygiene,’ which may lead to stigma, 199 
shame and reduced health-seeking. However, hygiene and handwashing do not affect the mite 200 
or transmission,95 and highly effective control has been demonstrated without any measures 201 
addressing hygiene or environment (see below),96 suggesting that associations with situations 202 
of poverty and disadvantage are likely due to poor access to healthcare and treatment, or the 203 
effects of overcrowding.21,97 The economic burden of scabies in some areas is thought to be 204 
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substantial, particularly due to the infestation leading to absence from employment and 205 
education, as well as the direct costs of accessing healthcare and repeated treatments (Figure 206 
3).98 Economic studies of the costs of scabies infestation and complications are needed to 207 
define and advocate for the most cost-effective control strategies. 208 
Treatment 209 
Although there are a number of effective, topical preparations for treatment of individual 210 
cases, for multiple reasons these agents are poorly suited to population-level control 211 
interventions. Reasons include the prolonged duration of application required and local 212 
irritation, resulting in inadequate adherence.99 Permethrin 5% cream is the most effective 213 
topical treatment,100 but is expensive and unavailable in most countries.21 Topical treatments 214 
that are available in some low- and middle-income countries include benzyl benzoate and 215 
sulphur ointments, but these are less well tolerated. Both options commonly cause skin 216 
irritation and stinging after application, and sulphur ointments are messy, malodourous and 217 
require repeat treatments.21 The effectiveness and safety profile of novel topical agents, 218 
including tea tree oil, for individual case management should be further explored.101-108 219 
Oral medicines have clear advantages for treatment of asymptomatic individuals, and 220 
particularly for treatment of whole populations through mass drug administration (MDA), 221 
where oral medications are more likely to be accepted and ingestion can be directly observed. 222 
Oral ivermectin is highly effective against scabies. Due to the lack of ovicidal action, a 223 
second treatment is usually recommended after 7-14 days for individual treatment, to kill 224 
newly hatched mites. A recent Cochrane review did not find any difference in efficacy when 225 
one dose was compared with two doses of ivermectin, or between oral ivermectin and topical 226 
permethrin.109 Although the strength of the review conclusions was limited by the quality of 227 
included studies, available evidence suggests that a single dose of ivermectin has some 228 
efficacy, and that two doses are likely to be comparably effective to permethrin for individual 229 
treatment. There is extensive experience on the feasibility and safety of using ivermectin for 230 
MDA for other NTDs such as lymphatic filariasis and onchocerciasis.110 231 
An oral agent with a longer duration of activity in the skin, that could persist for sufficient 232 
time to kill newly hatched mites, would obviate the need for a second dose and represent a 233 
major advance. Slow-release formulations of ivermectin have been developed, providing 234 
potential therapeutic effect for up to 6 months.111 These warrant further investigation for 235 
12 
scabies, although if the dosage form is large, administration to children may be challenging. 236 
Moxidectin, a macrocyclic lactone anti-parasitic agent related to ivermectin, has a half-life of 237 
up to 43 days, with prolonged activity in the skin.112,113 It is effective against Sarcoptes 238 
infestations in animals, and in a pre-clinical trial using a porcine-model of scabies, single 239 
dose moxidectin was superior to two doses of ivermectin based on the primary outcome 240 
measure of mite score.114 Moxidectin has recently been approved by the United States Food 241 
and Drug Administration (FDA) for treatment of onchocerciasis in individuals aged 12 years 242 
and above.115 Clinical trials of moxidectin for scabies have now commenced, with a plan to 243 
develop palatable products for children.116 244 
Research into scabies treatments also needs to consider safety, including treatment of 245 
pregnant and breastfeeding women and small children, groups that carry a disproportionate 246 
burden of scabies and are responsible for much its transmission. Administration of topical 247 
treatment to these groups during ivermectin-based MDA is a major cost and logistic issue. 248 
Due to the inadequacy of existing safety data, use of ivermectin in MDA programs for other 249 
NTDs has been restricted to those weighing over 15 kg or measuring above 90 cm (or aged 5 250 
years or older in some settings). It is worth noting, however, that several studies have 251 
reported no significant adverse outcomes from clinical and inadvertent public health use in 252 
young children.117,118 Further investigation of the safety of ivermectin in young children, and 253 
prospective data on the safety of moxidectin, are priorities. Ivermectin is considered a 254 
pregnancy category C drug by the FDA, but this determination is based on animal studies that 255 
used doses far in excess of those recommended for people.119 Studies comparing inadvertent 256 
treatment in pregnant women to controls have not demonstrated any concerning safety 257 
signal.120-123  In other NTD programs, ivermectin is offered when the risk of disease is 258 
considered higher than the theoretical risk to the foetus.124 In France, ivermectin is a 259 
recommended second-line treatment for scabies during pregnancy.125 Ivermectin is excreted 260 
in very low concentrations in human milk, and is generally regarded as safe in lactating 261 
women after the infant is 7 days old. Ivermectin can cause serious adverse events in 262 
individuals with high blood counts of Loa Loa microfilariae, a parasite found in Central 263 
Africa. Development of new diagnostic technologies such as the Loascope may enable safe 264 
delivery of ivermectin MDA in these areas,126 but further investigation of implementation is 265 
needed.127 266 
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In order to capitalise on existing MDA platforms for other NTDs, the safety of co-267 
administration of ivermectin with other medications needs to be established. In addition to the 268 
long-standing practice of co-administration with albendazole, large-scale studies have now 269 
demonstrated the safety of co-administration with azithromycin, opening the possibility of 270 
integrating control of scabies with control of yaws and/or trachoma.128-130 Similarly, early 271 
analysis of a multi-national safety cohort study of combination therapy of ivermectin, 272 
diethylcarbamazine and albendazole (IDA) for lymphatic filariasis did not reveal safety 273 
concerns and administration of this combination of agents has now been recommended for 274 
specific epidemiological contexts within WHO guidelines.131-134 275 
Monitoring for development of resistance of mites to acaricides will also be important. There 276 
have been isolated case reports of resistance to ivermectin in patients with crusted scabies 277 
who received repeated and prolonged treatment.135-137 Annual MDA may be less likely to 278 
promote the development of resistance than repeated individual treatments, but there is a lack 279 
of evidence on this subject.138 The proposed use of ivermectin MDA for malaria control 119,139 280 
could also promote resistance, particularly if a strategy of multiple doses each month is 281 
used.140 However, the risk of resistance seems to be greater for intestinal helminths than 282 
ectoparasites, based on experiences in livestock, where resistance to ivermectin among 283 
intestinal parasites is now widespread.141,142 Increasing use of topical treatments for other 284 
conditions in humans, such as permethrin for head lice and topical ivermectin for rosacea, 285 
may also promote resistance in scabies mites.143 286 
Detailed treatment guidelines for scabies have been developed in several high-income 287 
countries and regions, but recommendations vary.144-146 Standardised, evidence-based 288 
treatment guidelines for resource-limited settings, including individual case management and 289 
management of outbreaks in institutions or closed communities, would be valuable. Further 290 
investigation and development of guidelines for the appropriate treatment for individuals with 291 
crusted scabies in these settings, would also facilitate the success of control 292 
interventions.81,147-149 293 
Population-level control 294 
The strategy of individual case management has failed to appreciably reduce the transmission 295 
of scabies in high-prevalence settings.6,150 Recent data from studies using MDA have led to 296 
renewed interest in the potential of MDA to contribute to sustained population-level 297 
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control.151,152 Programs of mass treatment combined with additional screening and case 298 
management in Panama and Australia (using permethrin) 6,9,153 and the Solomon Islands 299 
(using ivermectin)154 considerably reduced scabies prevalence. Indirect evidence from 300 
Zanzibar suggested a reduction in consultations and prescriptions for scabies following 301 
annual MDA of ivermectin and albendazole for lymphatic filariasis155,156 but a study from a 302 
lower prevalence setting in mainland Tanzania did not show a sustained effect.157 However, 303 
in lymphatic filariasis control programs, children under 5 years are not given ivermectin (or 304 
any other agent active against scabies), which may explain ongoing transmission in this 305 
context.  The only controlled trial of community treatment published to date was conducted 306 
in small, relatively isolated island populations in Fiji, where a single round of ivermectin-307 
based MDA reduced the prevalence of scabies by 94%, in comparison to the permethrin-308 
based MDA (62% reduction) and screen-and-refer arms (49% reduction).158 These effects 309 
have now been shown to be sustained up to 24 months post intervention.159 The ivermectin-310 
based MDA intervention also resulted in a reduction of impetigo of 67% without adjunctive 311 
mass antibiotic treatment. Further work in the Solomon Islands using ivermectin-based MDA 312 
in a much larger population reported reductions in scabies prevalence of around 90%, and in 313 
impetigo prevalence of around 75%. 14,130 Conversely, ivermectin-based MDA for scabies in 314 
northern Australia was not associated with a sustained reduction in prevalence.79 The 315 
different results observed in the Australian study may have been due to increased interactions 316 
with surrounding untreated communities; lower baseline prevalence (4%, as compared to 32-317 
42% in the Fiji study); and transmission from untreated individuals with crusted scabies. 318 
These studies set the scene for further investigation of the role of programmatic MDA in 319 
scabies control. Priority future studies include investigation of whether a single dose of 320 
ivermectin (as opposed to two doses, 7 to 14 days apart) is sufficiently effective as MDA for 321 
scabies, and investigation of ivermectin-based MDA in other settings, including non-island 322 
populations where population mobility may be greater. While existing MDA data suggest 323 
effectiveness at high or very high population prevalence of 10 to 40%, the relative roles of 324 
MDA and case management at lower prevalence, for example, less than 10%, have not yet 325 
been adequately explored. Investigating the effect of MDA for scabies on complications such 326 
as skin and soft tissue infection, sepsis and autoimmune sequelae will be important, but 327 
require a large sample size and significant investment in infrastructure for active surveillance. 328 
Studies of moxidectin-based MDA should also be prioritised, if initial individually 329 
randomised clinical trials demonstrate efficacy. 330 
15 
Implementation research of integration of scabies control with other NTDs, particularly those 331 
affecting the skin, has the potential to demonstrate cost-efficient delivery of multiple health 332 
interventions.56,160 Initial studies could focus on understanding the impact of ivermectin-333 
based MDA for onchocerciasis and lymphatic filariasis on the prevalence of scabies in areas 334 
that are scaling up treatment, as well as the effect of cessation of MDA in areas that are 335 
scaling down treatment. There is concern that as ivermectin use for these programs is rolled 336 
back in some countries, there could be a resurgence of scabies infestation, which may be a 337 
major unintended consequence for communities. An additional research priority will be to 338 
investigate the feasibility and impact of adding topical scabies treatment of young children to 339 
existing ivermectin-based NTD programs. The possibility of developing a scabies vaccine has 340 
been considered, although this approach is still at an early stage of development.43,161,162  341 
Developing a global strategy 342 
Despite some deficiencies in the evidence for scabies control strategies, there is a need to 343 
develop preliminary recommendations that can be implemented by countries wishing to 344 
commence control measures, alongside pursuit of the research agenda described above. Initial 345 
guidance is required on the threshold of scabies prevalence above which MDA could be 346 
recommended, and other health system-related, geographic, socio-political or pragmatic 347 
factors that might affect this decision. In lower-prevalence settings, intensified case 348 
management strategies may be more appropriate. If MDA is to be utilised at large scale, then 349 
guidance will be required on the control target, number and frequency of MDA rounds, and 350 
monitoring and surveillance plan, including post-MDA surveillance, drawing on the lessons 351 
from other NTDs.163 This initial guidance should draw on the existing evidence-base, and—352 
acknowledging the limitations of current data—expert opinion and modelling work, with 353 
plans made for guidance to be refined as further evidence becomes available. If sustained 354 
control can be demonstrated, then it may be appropriate to consider the possibility of 355 
elimination (interruption of transmission) at a national or regional level. 356 
Once a mapping strategy is developed as part of a global control strategy, it will be possible 357 
to estimate the at-risk population requiring ivermectin and permethrin within individual 358 
countries and, with less certainty, at regional and global levels. Individual countries would be 359 
able to develop control plans as part of broader NTD strategies, taking into consideration the 360 
relative burden of scabies and other health issues. 361 
16 
It will be essential to advocate for access to affordable, quality-assured medications. 362 
Ivermectin has been generously donated through the Mectizan Donation Program for 363 
onchocerciasis and lymphatic filariasis in Africa and Latin America. This donation has 364 
recently expanded for use in countries where onchocerciasis is not endemic, as part of the 365 
IDA treatment strategy for lymphatic filariasis elimination.164 However, it is unclear if such a 366 
program could be extended to include scabies control as an indication. Although a donation 367 
program would maximise the likelihood of achieving control, low-cost, high-quality generic 368 
ivermectin may also be affordable in some settings. In addition to advocacy for donations, 369 
manufacturers of generic ivermectin could be supported to apply for WHO pre-qualification.3 370 
There is no precedent for a donation program for permethrin, and considerable amounts of it 371 
would be required for treatment of individuals for whom ivermectin is contraindicated. The 372 
licence holders of moxidectin, Medicines Development for Global Health, have committed to 373 
providing moxidectin at an affordable price for scabies control in low- and middle-income 374 
countries, if efficacy is demonstrated.116 375 
Conclusions 376 
Scabies is a common illness and major health issue affecting communities in many resource-377 
limited settings, and warrants public health intervention. There is strong evidence that 378 
ivermectin-based MDA strategies can be highly effective in reducing the burden of scabies 379 
and impetigo in at least some settings. Future research priorities include further defining the 380 
burden of disease, developing standardised approaches to diagnosis and population burden 381 
estimation, novel diagnostics and treatments, and evaluating large-scale community control 382 
strategies. Interim guidance on scabies control is now required. 383 
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Search strategy and selection criteria  840 
References for this review were identified through searches of PubMed for articles published 841 
from January, 1990, to March, 2019, using the terms “scabies” and “Sarcoptes scabiei.” 842 
Reference lists of identified manuscripts were reviewed to identify additional relevant 843 
material. No language restrictions were imposed.  844 
 845 
 846 
 847 
 848 
List of Acronyms 849 
DALY, disability-adjusted life year 850 
ELISA, enzyme-linked immunosorbent assay 851 
GBD, Global Burden of Disease 852 
IACS, International Alliance for the Control of Scabies 853 
IDA, ivermectin, diethylcarbamazine and albendazole  854 
LMIC, low- and middle-income countries 855 
NTD, neglected tropical disease 856 
MDA, mass drug administration 857 
US FDA, United States Food and Drug Administration  858 
WHO, World Health Organization 859 
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Panel 1. Key Research Questions 861 
Diagnosis 862 
• What is the accuracy and reproducibility of diagnosis using the 2018 IACS Criteria?  863 
• Can a limited skin examination protocol by non-expert health workers provide 864 
acceptable accuracy for estimating prevalence? 865 
• Can accurate skin-sample or blood tests be developed for scabies diagnosis? 866 
Epidemiology and mapping 867 
• What is the global burden of scabies? Which countries have the highest burdens of 868 
scabies? 869 
• What is the at-risk population living in highly-endemic settings? 870 
• Are there identifiable risk factors for areas of high prevalence? 871 
• What is the correlation between prevalence in school-attending children and the 872 
community? 873 
Transmission and complications 874 
• What are the transmission dynamics of scabies? 875 
• To what extent does crusted scabies drive transmission in highly endemic settings? 876 
• What is the association between scabies and impetigo outside the Pacific region? 877 
Social and economic 878 
• What is the social burden of scabies as perceived and understood by affected 879 
communities? 880 
• What is the acceptability of MDA for scabies to affected communities? 881 
• What approaches can effectively engage communities to support scabies control 882 
initiatives? 883 
Treatments 884 
• Can ivermectin or other oral agents be safely administered to children of height < 90 885 
cm, weight <15 kg or age <5 years? 886 
• Are novel topical agents as effective, better tolerated or more affordable than 887 
permethrin? 888 
• What is the effectiveness of moxidectin for individual treatment and MDA for 889 
scabies? 890 
Mass drug administration for scabies 891 
• What is the optimal dose and dosing strategy of ivermectin for MDA? 892 
• What is the optimal interval between rounds of MDA? 893 
• What is the impact of MDA for scabies on the burden of impetigo, severe bacterial 894 
soft-tissue and systemic infections, glomerulonephritis and rheumatic heart disease? 895 
• Under what conditions would MDA for scabies be cost-effective? 896 
• How can ivermectin-based MDA for scabies be safely and effectively integrated 897 
and/or co-administered with MDA for other NTDs? 898 
Control strategy 899 
• In what circumstances (threshold scabies prevalence or other factors) should MDA 900 
and intensified case management strategies be used? 901 
• If MDA is not being used, how can intensified case management be implemented?  902 
33 
• What are the effects of ivermectin-based MDA programs for other NTDs on scabies? 903 
What happens to scabies prevalence when these programs cease? 904 
• What is the feasibility and effect of adding permethrin treatment of young children to 905 
existing ivermectin-based MDA programs for other NTDs? 906 
• What, if any, environmental measures should be recommended? 907 
 908 
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Panel 2. Key Programmatic Issues 910 
Epidemiology 911 
• Development of a protocol and training package for scabies mapping 912 
• Mapping scabies prevalence using standardised methods, focusing on LMIC 913 
• Integrated surveys with other NTD and health programs 914 
• Surveillance strategies for potential outbreaks in high-risk settings 915 
• Understanding high-burden groups within high-income settings 916 
 917 
Population-level Control 918 
• Interim guidance for public health control of scabies, including thresholds for starting 919 
and stopping MDA, number and frequency of rounds, drugs and doses. 920 
• Interim guidance on control of scabies outbreaks in institutions and communities 921 
• Monitoring and evaluation strategy for impact of interventions on scabies 922 
• Monitoring and evaluation strategy for impact of interventions on scabies 923 
complications and other conditions. 924 
• Monitoring for resistance 925 
 926 
Strategy 927 
• Define a global control strategy with targets 928 
• Affordable and reliable access to oral and topical medications for treatment 929 
• Ivermectin listing on WHO Essential Medicines List for scabies indication 930 
• Integration with programs for other NTDs and other health programs 931 
• Develop proposal for a future World Health Assembly resolution 932 
 933 
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FIGURE LEGEND 
Figure 1: Child’s feet with skin manifestations of scabies infestation and secondary 
pyoderma 
Photo courtesy Millicent Osti 
 
 
Figure 2: Prevalence of scabies in children and adolescents younger than 19 years 
Prevalence is shown at the country level, using available data from Romani et al., 20154 and 
updated with additional references.8,10-17 Subnational variation exists but is not represented in 
the map. 
 
 
Figure 3: Primary and secondary effects of scabies infestation 
 
 
 
 
